Transcription	B-protein
factor	I-protein
AP-2	I-protein
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O

The	O
HTLV-I	B-DNA
LTR	I-DNA
contains	O
three	O
conserved	O
regulatory	B-DNA
elements	I-DNA
known	O
as	O
21	B-DNA
base	I-DNA
pair	I-DNA
repeats	I-DNA
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	B-protein
protein	I-protein
tax	B-protein
.	O

Mutagenesis	O
indicates	O
that	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	B-protein
activation	O
.	O

The	O
A	B-DNA
site	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	B-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
AP-2	I-protein
.	O

We	O
demonstrated	O
that	O
AP-2	B-RNA
mRNA	I-RNA
was	O
present	O
in	O
T-lymphocytes	B-cell_type
and	O
that	O
cellular	O
factors	O
from	O
both	O
non-transformed	O
and	O
transformed	O
T-lymphocytes	B-cell_type
specifically	O
bound	O
to	O
the	O
consensus	B-DNA
motif	I-DNA
for	O
AP-2	B-protein
in	O
each	O
21	O
bp	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP-2	B-protein
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	B-DNA
cDNA	I-DNA
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	B-protein
produced	I-protein
AP-2	I-protein
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
,	O
and	O
that	O
it	O
required	O
the	O
core	B-DNA
sequence	I-DNA
AGGC	O
for	O
specific	O
binding	O
.	O

Binding	O
of	O
AP-2	B-protein
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB/ATF	B-protein
family	I-protein
to	O
an	O
adjacent	B-DNA
regulatory	I-DNA
motif	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeat	I-DNA
.	O

Transfection	O
of	O
an	O
AP-2	B-DNA
expression	I-DNA
construct	I-DNA
into	O
T-lymphocytes	B-cell_type
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	B-DNA
LTR	I-DNA
.	O

At	O
least	O
two	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
were	O
required	O
for	O
high	O
levels	O
of	O
AP-2	B-protein
activation	O
and	O
mutagenesis	O
of	O
the	O
AP-2	B-DNA
consensus	I-DNA
binding	I-DNA
sequences	I-DNA
in	O
the	O
21	B-DNA
bp	I-DNA
repeats	I-DNA
eliminate	O
this	O
activation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	NULL
EMBO	NULL
Journal	NULL
vol.11	NULL
no.7	NULL
pp.2573-2581	NULL
,	NULL
1992	NULL
Transcription	NULL
factor	NULL
AP-2	NULL
activates	NULL
gene	NULL
expression	NULL
of	NULL
HTLV-I	NULL
Christian	NULL
Muchardt	NULL
,	NULL
Jacob-S.Seeler	NULL
,	NULL
Ajay	NULL
Nirula	NULL
,	NULL
Shiaoching	NULL
Gong	NULL
and	NULL
Richard	NULL
Gaynor	NULL
Division	NULL
of	NULL
Molecular	NULL
Virology	NULL
,	NULL
Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
at	NULL
Dallas	NULL
,	NULL
Dallas	NULL
,	NULL
Texas	NULL
,	NULL
USA	NULL
Communicated	NULL
by	NULL
P.Boulanger	NULL
The	NULL
HTLV-I	NULL
LTR	NULL
contains	NULL
three	NULL
conserved	NULL
regulatory	NULL
elements	NULL
known	NULL
as	NULL
21	NULL
base	NULL
pair	NULL
repeats	NULL
which	NULL
are	NULL
required	NULL
for	NULL
stimulation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
transactivator	NULL
protein	NULL
tax	NULL
.	NULL

Mutagenesis	NULL
indicates	NULL
that	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
can	NULL
be	NULL
subdivided	NULL
into	NULL
three	NULL
motifs	NULL
,	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
each	NULL
of	NULL
which	NULL
influences	NULL
the	NULL
level	NULL
of	NULL
tax	NULL
activation	NULL
.	NULL

The	NULL
A	NULL
site	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
has	NULL
strong	NULL
homology	NULL
with	NULL
previously	NULL
described	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
AP-2	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
AP-2	NULL
mRNA	NULL
was	NULL
present	NULL
in	NULL
T-lymphocytes	NULL
and	NULL
that	NULL
cellular	NULL
factors	NULL
from	NULL
both	NULL
non-transformed	NULL
and	NULL
transformed	NULL
T-lymphocytes	NULL
specifically	NULL
bound	NULL
to	NULL
the	NULL
consensus	NULL
motif	NULL
for	NULL
AP-2	NULL
in	NULL
each	NULL
21	NULL
bp	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
role	NULL
of	NULL
AP-2	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
used	NULL
an	NULL
AP-2	NULL
cDNA	NULL
in	NULL
DNA	NULL
binding	NULL
and	NULL
transient	NULL
expression	NULL
assays	NULL
.	NULL

Gel	NULL
retardation	NULL
and	NULL
methylation	NULL
interference	NULL
studies	NULL
revealed	NULL
that	NULL
bacterially	NULL
produced	NULL
AP-2	NULL
bound	NULL
specifically	NULL
and	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
all	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
,	NULL
and	NULL
that	NULL
it	NULL
required	NULL
the	NULL
core	NULL
sequence	NULL
AGGC	NULL
for	NULL
specific	NULL
binding	NULL
.	NULL

Binding	NULL
of	NULL
AP-2	NULL
prevented	NULL
the	NULL
subsequent	NULL
binding	NULL
of	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
to	NULL
an	NULL
adjacent	NULL
regulatory	NULL
motif	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

Transfection	NULL
of	NULL
an	NULL
AP-2	NULL
expression	NULL
construct	NULL
into	NULL
T-lymphocytes	NULL
activated	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
.	NULL

At	NULL
least	NULL
two	NULL
21	NULL
bp	NULL
repeats	NULL
were	NULL
required	NULL
for	NULL
high	NULL
levels	NULL
of	NULL
AP-2	NULL
activation	NULL
and	NULL
mutagenesis	NULL
of	NULL
the	NULL
AP-2	NULL
consensus	NULL
binding	NULL
sequences	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
eliminate	NULL
this	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
AP-2	NULL
is	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
and	NULL
activating	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
,	NULL
and	NULL
thus	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
this	NULL
important	NULL
human	NULL
retrovirus	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
21	NULL
bp	NULL
repeat/	NULL
AP-2/HTLV-l/tax	NULL
Introduction	NULL
The	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
is	NULL
the	NULL
causative	NULL
agent	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
(	NULL
Poiesz	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1980	NULL
,	NULL
1981	NULL
;	NULL
Yoshida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

HTLV-I	NULL
is	NULL
also	NULL
associated	NULL
with	NULL
a	NULL
progressive	NULL
demyelinating	NULL
syndrome	NULL
known	NULL
as	NULL
tropical	NULL
spastic	NULL
paraparesis	NULL
(	NULL
Gessain	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Osame	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

HTLV-I	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
infect	NULL
CD4*	NULL
T-lymphocytes	NULL
and	NULL
to	NULL
immortalize	NULL
these	NULL
cells	NULL
.	NULL

A	NULL
40	NULL
kDa	NULL
protein	NULL
encoded	NULL
by	NULL
HTLV-I	NULL
known	NULL
as	NULL
tax	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
transforming	NULL
properties	NULL
of	NULL
this	NULL
virus	NULL
(	NULL
Hinrichs	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Wano	NULL
â‚¬	NULL
Oxford	NULL
University	NULL
Press	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Pozzati	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Tanaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
tax	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
viral	NULL
gene	NULL
expression	NULL
(	NULL
Sodroski	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Felber	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Smith	NULL
and	NULL
Greene	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
properties	NULL
of	NULL
tax	NULL
which	NULL
mediate	NULL
both	NULL
its	NULL
transcriptional	NULL
and	NULL
transforming	NULL
activities	NULL
have	NULL
been	NULL
the	NULL
subject	NULL
of	NULL
intense	NULL
investigation	NULL
.	NULL

At	NULL
least	NULL
two	NULL
different	NULL
elements	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
are	NULL
critical	NULL
for	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

One	NULL
element	NULL
with	NULL
the	NULL
repeated	NULL
sequence	NULL
CC	NULL
(	NULL
A/T	NULL
)	NULL
CC	NULL
serves	NULL
as	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
Bosselut	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Gitlin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Both	NULL
ets-1	NULL
and	NULL
ets-2	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
capable	NULL
of	NULL
activating	NULL
gene	NULL
expression	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
CAT	NULL
constructs	NULL
in	NULL
cotransfection	NULL
experiments	NULL
(	NULL
Bosselut	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
second	NULL
element	NULL
which	NULL
is	NULL
critical	NULL
for	NULL
gene	NULL
expression	NULL
of	NULL
the	NULL
HTLV	NULL
LTR	NULL
is	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
(	NULL
Fujisawa	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Paskalis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Shimotohno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Brady	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Rosen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Three	NULL
of	NULL
these	NULL
highly	NULL
conserved	NULL
repeats	NULL
are	NULL
present	NULL
in	NULL
different	NULL
portions	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
and	NULL
mutagenesis	NULL
studies	NULL
indicate	NULL
that	NULL
at	NULL
least	NULL
two	NULL
21	NULL
bp	NULL
repeats	NULL
are	NULL
required	NULL
for	NULL
a	NULL
high	NULL
level	NULL
of	NULL
induction	NULL
by	NULL
tax	NULL
(	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Brady	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
and	NULL
potentially	NULL
other	NULL
elements	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
are	NULL
critical	NULL
for	NULL
tax	NULL
activation	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
indicates	NULL
that	NULL
it	NULL
can	NULL
be	NULL
subdivided	NULL
into	NULL
three	NULL
distinct	NULL
motifs	NULL
known	NULL
as	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
(	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
B	NULL
motif	NULL
contains	NULL
the	NULL
core	NULL
sequence	NULL
TGAGG	NULL
which	NULL
serves	NULL
as	NULL
a	NULL
potential	NULL
binding	NULL
site	NULL
for	NULL
members	NULL
of	NULL
the	NULL
ATF/CREB	NULL
family	NULL
(	NULL
Hai	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
A	NULL
and	NULL
C	NULL
motifs	NULL
which	NULL
flank	NULL
the	NULL
B	NULL
motif	NULL
contain	NULL
the	NULL
core	NULL
recognition	NULL
sequences	NULL
AGGC	NULL
and	NULL
CCCC	NULL
respectively	NULL
.	NULL

Mutagenesis	NULL
of	NULL
the	NULL
B	NULL
motif	NULL
eliminates	NULL
tax	NULL
activation	NULL
(	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
while	NULL
mutagenesis	NULL
of	NULL
both	NULL
the	NULL
A	NULL
and	NULL
C	NULL
motifs	NULL
also	NULL
result	NULL
in	NULL
severe	NULL
decreases	NULL
in	NULL
tax-mediated	NULL
activation	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
(	NULL
Montagne	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
are	NULL
composed	NULL
of	NULL
different	NULL
motifs	NULL
each	NULL
of	NULL
which	NULL
may	NULL
be	NULL
required	NULL
for	NULL
complete	NULL
activation	NULL
by	NULL
the	NULL
tax	NULL
protein	NULL
.	NULL

Since	NULL
tax	NULL
does	NULL
not	NULL
directly	NULL
bind	NULL
to	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
,	NULL
its	NULL
role	NULL
in	NULL
increasing	NULL
gene	NULL
expression	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
interaction	NULL
with	NULL
cellular	NULL
factors	NULL
bound	NULL
to	NULL
the	NULL
LTR	NULL
(	NULL
Marriot	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
BÃ©raud	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
different	NULL
cellular	NULL
factors	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
(	NULL
Altman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Jeang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Nyborg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
,	NULL
1990	NULL
;	NULL
Tan	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1989a	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
BÃ©raud	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

At	NULL
least	NULL
eight	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
core	NULL
sequence	NULL
TGACG	NULL
found	NULL
in	NULL
the	NULL
B	NULL
motif	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
(	NULL
Hai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Tsujimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Fractionation	NULL
of	NULL
cellular	NULL
extracts	NULL
and	NULL
DNase	NULL
I	NULL
footprinting	NULL
reveals	NULL
that	NULL
AP-2	NULL
or	NULL
related	NULL
factors	NULL
bind	NULL
over	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
,	NULL
though	NULL
which	NULL
nucleotides	NULL
are	NULL
critical	NULL
for	NULL
this	NULL
binding	NULL
remain	NULL
2573	NULL
C.Muchardt	NULL
et	NULL
af	NULL
.	NULL

unclear	NULL
(	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
other	NULL
less	NULL
well	NULL
defined	NULL
factors	NULL
have	NULL
also	NULL
been	NULL
demonstrated	NULL
to	NULL
bind	NULL
to	NULL
different	NULL
motifs	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
(	NULL
Tan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Montagne	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
BÃ©raud	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
explore	NULL
the	NULL
binding	NULL
and	NULL
regulation	NULL
of	NULL
AP-2	NULL
(	NULL
Williams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Williams	NULL
and	NULL
Tjian	NULL
,	NULL
1991a	NULL
and	NULL
b	NULL
)	NULL
to	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
AP-2	NULL
mRNA	NULL
is	NULL
expressed	NULL
in	NULL
T-lymphocytes	NULL
and	NULL
that	NULL
proteins	NULL
from	NULL
both	NULL
T-lymphocytes	NULL
and	NULL
HeLa	NULL
cells	NULL
bind	NULL
specifically	NULL
and	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
the	NULL
AGGC	NULL
sequence	NULL
within	NULL
the	NULL
A	NULL
motif	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

Likewise	NULL
,	NULL
proteins	NULL
produced	NULL
in	NULL
bacteria	NULL
from	NULL
an	NULL
AP-2	NULL
cDNA	NULL
also	NULL
binds	NULL
to	NULL
this	NULL
motif	NULL
and	NULL
the	NULL
binding	NULL
of	NULL
AP-2	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
excludes	NULL
the	NULL
subsequent	NULL
binding	NULL
of	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
AP-2	NULL
can	NULL
activate	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
.	NULL

These	NULL
studies	NULL
describe	NULL
the	NULL
role	NULL
of	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
AP-2	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
HTLV-I	NULL
LTR	NULL
gene	NULL
expression	NULL
.	NULL

Results	NULL
HTLV-I	NULL
LTR	NULL
21	NULL
bp	NULL
repeats	NULL
contain	NULL
sequences	NULL
with	NULL
homology	NULL
to	NULL
AP-2	NULL
binding	NULL
sites	NULL
A	NULL
schematic	NULL
diagram	NULL
of	NULL
the	NULL
position	NULL
of	NULL
the	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
relative	NULL
to	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
and	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
each	NULL
of	NULL
the	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
1A	NULL
.	NULL

Binding	NULL
assays	NULL
and	NULL
transfection	NULL
experiments	NULL
with	NULL
mutagenized	NULL
21	NULL
bp	NULL
repeat	NULL
constructs	NULL
were	NULL
consistent	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
can	NULL
be	NULL
further	NULL
subdivided	NULL
into	NULL
three	NULL
regulatory	NULL
motifs	NULL
known	NULL
as	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
each	NULL
of	NULL
which	NULL
have	NULL
distinct	NULL
regulatory	NULL
properties	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
(	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Examination	NULL
of	NULL
the	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
A	NULL
motif	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
revealed	NULL
strong	NULL
homology	NULL
to	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
AP-2	NULL
which	NULL
has	NULL
previously	NULL
been	NULL
defined	NULL
in	NULL
the	NULL
SV40	NULL
and	NULL
metallothionein	NULL
enhancers	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
(	NULL
Mitchell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Imagawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
highest	NULL
degree	NULL
of	NULL
homology	NULL
with	NULL
SV40	NULL
was	NULL
found	NULL
in	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
,	NULL
with	NULL
a	NULL
lower	NULL
degree	NULL
of	NULL
homology	NULL
found	NULL
in	NULL
repeats	NULL
I	NULL
and	NULL
II	NULL
.	NULL

The	NULL
sequence	NULL
AGGC	NULL
was	NULL
completely	NULL
conserved	NULL
in	NULL
the	NULL
A	NULL
motif	NULL
of	NULL
all	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
.	NULL

AP-2	NULL
is	NULL
present	NULL
in	NULL
T-lymphocytes	NULL
Since	NULL
HTLV-I	NULL
can	NULL
infect	NULL
and	NULL
transform	NULL
T-lymphocytes	NULL
,	NULL
we	NULL
first	NULL
determined	NULL
whether	NULL
AP-2	NULL
mRNA	NULL
was	NULL
expressed	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Primers	NULL
were	NULL
synthesized	NULL
to	NULL
regions	NULL
of	NULL
the	NULL
published	NULL
AP-2	NULL
cDNA	NULL
sequence	NULL
(	NULL
Williams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
and	NULL
used	NULL
in	NULL
polymerase	NULL
chain	NULL
reaction	NULL
with	NULL
total	NULL
RNA	NULL
isolated	NULL
from	NULL
the	NULL
Jurkat	NULL
T-lymphocyte	NULL
cell	NULL
line	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
2	NULL
,	NULL
four	NULL
products	NULL
were	NULL
synthesized	NULL
in	NULL
the	NULL
PCR	NULL
reaction	NULL
.	NULL

These	NULL
products	NULL
were	NULL
all	NULL
cloned	NULL
and	NULL
analyzed	NULL
by	NULL
DNA	NULL
sequencing	NULL
.	NULL

The	NULL
560	NULL
bp	NULL
product	NULL
had	NULL
a	NULL
sequence	NULL
identical	NULL
to	NULL
the	NULL
published	NULL
AP-2	NULL
cDNA	NULL
sequence	NULL
(	NULL
Williams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

A	NULL
smaller	NULL
product	NULL
of	NULL
~290	NULL
bp	NULL
(	NULL
II	NULL
)	NULL
appeared	NULL
to	NULL
be	NULL
an	NULL
alternatively	NULL
spliced	NULL
product	NULL
of	NULL
AP-2	NULL
mRNA	NULL
which	NULL
introduced	NULL
a	NULL
stop	NULL
codon	NULL
prematurely	NULL
into	NULL
the	NULL
AP-2	NULL
coding	NULL
sequence	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Two	NULL
other	NULL
products	NULL
of	NULL
170	NULL
and	NULL
90	NULL
bp	NULL
could	NULL
not	NULL
be	NULL
related	NULL
to	NULL
the	NULL
AP-2	NULL
cDNA	NULL
sequence	NULL
and	NULL
were	NULL
probably	NULL
PCR	NULL
artifacts	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
PCR	NULL
products	NULL
was	NULL
seen	NULL
in	NULL
HUT78	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Next	NULL
we	NULL
determined	NULL
whether	NULL
factors	NULL
present	NULL
in	NULL
either	NULL
Jurkat	NULL
cells	NULL
or	NULL
an	NULL
HTLV-I	NULL
transformed	NULL
T-lymphocyte	NULL
cell	NULL
line	NULL
,	NULL
SLB	NULL
(	NULL
Koeffler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
,	NULL
bound	NULL
to	NULL
an	NULL
AP-2	NULL
binding	NULL
site	NULL
.	NULL

Labeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
a	NULL
high	NULL
affinity	NULL
AP-2	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
human	NULL
metallothionein	NULL
promoter	NULL
(	NULL
Imagawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
with	NULL
protein	NULL
obtained	NULL
from	NULL
an	NULL
in	NULL
vitro	NULL
translated	NULL
AP-2	NULL
cDNA	NULL
and	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
Jurkat	NULL
,	NULL
SLB	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

A	NULL
gel	NULL
retarded	NULL
species	NULL
was	NULL
seen	NULL
in	NULL
Jurkat	NULL
,	NULL
SLB	NULL
and	NULL
HeLa	NULL
extracts	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lanes	NULL
3-5	NULL
)	NULL
that	NULL
comigrated	NULL
closely	NULL
with	NULL
a	NULL
species	NULL
denoted	NULL
by	NULL
I	NULL
obtained	NULL
from	NULL
the	NULL
in	NULL
vitro	NULL
translated	NULL
AP-2	NULL
cDNA	NULL
which	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
unprogrammed	NULL
reticulocyte	NULL
lysate	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

UV	NULL
crosslinking	NULL
revealed	NULL
that	NULL
the	NULL
species	NULL
detected	NULL
in	NULL
HeLa	NULL
,	NULL
SLB	NULL
or	NULL
Jurkat	NULL
cell	NULL
lines	NULL
has	NULL
a	NULL
mol	NULL
.	NULL

wt	NULL
of	NULL
50	NULL
kDa	NULL
which	NULL
is	NULL
close	NULL
to	NULL
the	NULL
predicted	NULL
mol	NULL
.	NULL

wt	NULL
of	NULL
AP-2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
demonstrate	NULL
the	NULL
specificity	NULL
of	NULL
this	NULL
binding	NULL
,	NULL
SLB	NULL
extract	NULL
was	NULL
used	NULL
in	NULL
a	NULL
competition	NULL
experiment	NULL
with	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
a	NULL
wild-type	NULL
21	NULL
bp	NULL
repeat	NULL
or	NULL
a	NULL
21	NULL
bp	NULL
repeat	NULL
mutated	NULL
in	NULL
the	NULL
A	NULL
site	NULL
.	NULL

The	NULL
slow	NULL
mobility	NULL
species	NULL
found	NULL
in	NULL
SLB	NULL
extract	NULL
that	NULL
comigrated	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
AP-2	NULL
(	NULL
Figure	NULL
3B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
completely	NULL
competed	NULL
with	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
wild-type	NULL
21	NULL
bp	NULL
III	NULL
(	NULL
Figure	NULL
3B	NULL
,	NULL
lanes	NULL
2-4	NULL
)	NULL
but	NULL
not	NULL
with	NULL
oligonucleotides	NULL
lacking	NULL
these	NULL
sites	NULL
(	NULL
Figure	NULL
3B	NULL
,	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
both	NULL
AP-2	NULL
RNA	NULL
and	NULL
protein	NULL
was	NULL
presented	NULL
in	NULL
T-lymphocytes	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
.	NULL

Consensus	NULL
binding	NULL
sequences	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
schematic	NULL
diagram	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
is	NULL
shown	NULL
with	NULL
the	NULL
positions	NULL
and	NULL
sequences	NULL
of	NULL
the	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
,	NULL
the	NULL
ets	NULL
binding	NULL
sites	NULL
and	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Regions	NULL
in	NULL
either	NULL
the	NULL
SV40	NULL
or	NULL
metallothionein	NULL
promoters	NULL
which	NULL
bind	NULL
AP-2	NULL
are	NULL
compared	NULL
with	NULL
potential	NULL
AP-2	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeats	NULL
.	NULL

2574	NULL
AP-2	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeat	NULL
A	NULL
motif	NULL
Our	NULL
studies	NULL
suggested	NULL
that	NULL
AP-2	NULL
bound	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

To	NULL
elucidate	NULL
further	NULL
the	NULL
role	NULL
of	NULL
AP-2	NULL
in	NULL
regulating	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
,	NULL
a	NULL
cDNA	NULL
encoding	NULL
the	NULL
complete	NULL
AP-2	NULL
protein	NULL
isolated	NULL
from	NULL
a	NULL
HeLa	NULL
cell	NULL
AZAP	NULL
cDNA	NULL
library	NULL
(	NULL
Williams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Williams	NULL
and	NULL
Tjian	NULL
,	NULL
1991a	NULL
,	NULL
b	NULL
)	NULL
was	NULL
cloned	NULL
downstream	NULL
of	NULL
the	NULL
glutathione-S-transferase	NULL
(	NULL
GST	NULL
)	NULL
gene	NULL
in	NULL
the	NULL
plasmid	NULL
pGEX-2T	NULL
(	NULL
Smith	NULL
and	NULL
Johnson	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

This	NULL
clone	NULL
made	NULL
it	NULL
possible	NULL
to	NULL
obtain	NULL
high	NULL
level	NULL
expression	NULL
of	NULL
this	NULL
gene	NULL
product	NULL
in	NULL
Escherichia	NULL
coli	NULL
.	NULL

Following	NULL
affinity	NULL
purification	NULL
of	NULL
this	NULL
AP-2	NULL
fusion	NULL
protein	NULL
by	NULL
glutathione	NULL
-Sepharose	NULL
chromatography	NULL
,	NULL
both	NULL
the	NULL
GST/AP-2	NULL
fusion	NULL
and	NULL
native	NULL
AP-2	NULL
protein	NULL
obtained	NULL
following	NULL
cleavage	NULL
of	NULL
the	NULL
fusion	NULL
protein	NULL
by	NULL
thrombin	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
assays	NULL
with	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
each	NULL
of	NULL
the	NULL
three	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeats	NULL
.	NULL

The	NULL
gel	NULL
retardation	NULL
results	NULL
were	NULL
similar	NULL
using	NULL
both	NULL
authentic	NULL
AP-2	NULL
and	NULL
the	NULL
GST/AP-2	NULL
fusion	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

AP-2	NULL
activation	NULL
of	NULL
HTLV-I	NULL
Only	NULL
the	NULL
results	NULL
with	NULL
the	NULL
GST/AP-2	NULL
fusions	NULL
referred	NULL
to	NULL
hereafter	NULL
as	NULL
AP-2	NULL
are	NULL
shown	NULL
.	NULL

AP-2	NULL
(	NULL
Figure	NULL
4	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
and	NULL
6	NULL
)	NULL
but	NULL
not	NULL
control	NULL
bacterial	NULL
extract	NULL
containing	NULL
the	NULL
glutathione-S-transferase	NULL
protein	NULL
alone	NULL
(	NULL
Figure	NULL
4	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
and	NULL
5	NULL
)	NULL
was	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
each	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
AP-2	NULL
was	NULL
stronger	NULL
to	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
(	NULL
Figure	NULL
4	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
than	NULL
for	NULL
21	NULL
bp	NULL
repeats	NULL
I	NULL
and	NULL
II	NULL
(	NULL
Figure	NULL
4	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
has	NULL
the	NULL
strongest	NULL
homology	NULL
to	NULL
the	NULL
SV40	NULL
and	NULL
the	NULL
metallothionein	NULL
AP-2	NULL
binding	NULL
sites	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
specificity	NULL
of	NULL
AP-2	NULL
binding	NULL
,	NULL
gel	NULL
retardation	NULL
with	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
was	NULL
performed	NULL
as	NULL
was	NULL
competition	NULL
with	NULL
both	NULL
wild-type	NULL
and	NULL
mutated	NULL
unlabeled	NULL
oligonucleotides	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
wild-type	NULL
21	NULL
bp	NULL
repeat	NULL
competed	NULL
AP-2	NULL
binding	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
as	NULL
did	NULL
oligonucleotides	NULL
containing	NULL
mutations	NULL
of	NULL
either	NULL
the	NULL
B	NULL
or	NULL
C	NULL
sites	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

However	NULL
,	NULL
oligonucleotides	NULL
containing	NULL
mutations	NULL
of	NULL
the	NULL
A	NULL
site	NULL
either	NULL
alone	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

T-lymphocytes	NULL
produce	NULL
AP-2	NULL
RNA	NULL
.	NULL

PCR	NULL
are	NULL
performed	NULL
on	NULL
RNA	NULL
isolated	NULL
cells	NULL
from	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
PCR	NULL
products	NULL
(	NULL
I-IV	NULL
)	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
are	NULL
shown	NULL
next	NULL
to	NULL
a	NULL
DNA	NULL
size	NULL
standard	NULL
(	NULL
M	NULL
)	NULL
following	NULL
gel	NULL
electrophoresis	NULL
.	NULL

A	NULL
sample	NULL
of	NULL
Jurkat	NULL
RNA	NULL
which	NULL
was	NULL
subject	NULL
to	NULL
PCR	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
reverse	NULL
transcription	NULL
is	NULL
also	NULL
shown	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
cloned	NULL
into	NULL
pUC19	NULL
and	NULL
subjected	NULL
to	NULL
DNA	NULL
sequence	NULL
analysis	NULL
.	NULL

A	NULL
schematic	NULL
diagram	NULL
is	NULL
shown	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
I	NULL
and	NULL
II	NULL
which	NULL
each	NULL
correspond	NULL
to	NULL
AP-2	NULL
cDNA	NULL
sequences	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
.	NULL

SLB	NULL
and	NULL
Jurkat	NULL
T-lymphocyte	NULL
cell	NULL
lines	NULL
contain	NULL
an	NULL
AP-2	NULL
binding	NULL
activity	NULL
.	NULL

Oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
AP-2	NULL
site	NULL
in	NULL
the	NULL
metallothionein	NULL
promoter	NULL
were	NULL
end-labeled	NULL
and	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
assays	NULL
(	NULL
A	NULL
)	NULL
with	NULL
reticulocyte	NULL
lysate	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
reticulocyte	NULL
lysate	NULL
.	NULL

programmed	NULL
with	NULL
AP-2	NULL
mRNA	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
SLB	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
Jurkat	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Arrow	NULL
1	NULL
indicates	NULL
the	NULL
AP-2	NULL
gel	NULL
retarded	NULL
species	NULL
and	NULL
arrow	NULL
2	NULL
indicates	NULL
an	NULL
AP-2	NULL
binding	NULL
activity	NULL
found	NULL
in	NULL
the	NULL
reticulocyte	NULL
lysate	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Competition	NULL
using	NULL
SLB	NULL
nuclear	NULL
extract	NULL
was	NULL
performed	NULL
with	NULL
0	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
50	NULL
ng	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
100	NULL
ng	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
200	NULL
ng	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
of	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
wild-type	NULL
21	NULL
bp	NULL
III	NULL
or	NULL
50	NULL
ng	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
100	NULL
ng	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
or	NULL
200	NULL
ng	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
of	NULL
21	NULL
bp	NULL
III	NULL
mutated	NULL
in	NULL
the	NULL
AP-2	NULL
binding	NULL
site	NULL
.	NULL

2575	NULL
C.Muchardt	NULL
et	NULL
al	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
.	NULL

AP-2	NULL
binds	NULL
to	NULL
each	NULL
of	NULL
the	NULL
three	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeats	NULL
.	NULL

Oligonucleotides	NULL
corresponding	NULL
to	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeats	NULL
I	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
II	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
and	NULL
III	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
with	NULL
bacterial	NULL
extract	NULL
containing	NULL
either	NULL
glutathione	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
and	NULL
5	NULL
)	NULL
or	NULL
GST/AP-2	NULL
fusion	NULL
protein	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

lane	NULL
4	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
mutations	NULL
of	NULL
either	NULL
or	NULL
both	NULL
of	NULL
the	NULL
B	NULL
and	NULL
C	NULL
sites	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
did	NULL
not	NULL
result	NULL
in	NULL
significant	NULL
competition	NULL
for	NULL
AP-2	NULL
binding	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
AP-2	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
A	NULL
site	NULL
within	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
seen	NULL
with	NULL
21	NULL
bp	NULL
repeats	NULL
I	NULL
and	NULL
II	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Next	NULL
we	NULL
determined	NULL
the	NULL
specific	NULL
contact	NULL
points	NULL
within	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
required	NULL
for	NULL
AP-2	NULL
binding	NULL
.	NULL

Methylation	NULL
interference	NULL
studies	NULL
were	NULL
performed	NULL
using	NULL
partially	NULL
methylated	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
the	NULL
coding	NULL
or	NULL
non-coding	NULL
strands	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
.	NULL

Following	NULL
gel	NULL
retardation	NULL
analysis	NULL
with	NULL
AP-2	NULL
,	NULL
the	NULL
gel	NULL
retarded	NULL
species	NULL
was	NULL
removed	NULL
,	NULL
purified	NULL
,	NULL
cleaved	NULL
with	NULL
piperidine	NULL
and	NULL
electrophoresed	NULL
,	NULL
and	NULL
autoradiography	NULL
was	NULL
performed	NULL
.	NULL

Methylation	NULL
of	NULL
the	NULL
non-coding	NULL
strand	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
revealed	NULL
that	NULL
four	NULL
G	NULL
residues	NULL
in	NULL
the	NULL
A	NULL
domain	NULL
and	NULL
upstream	NULL
region	NULL
were	NULL
protected	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
,	NULL
while	NULL
on	NULL
the	NULL
coding	NULL
strand	NULL
two	NULL
G	NULL
residues	NULL
in	NULL
the	NULL
A	NULL
domain	NULL
were	NULL
protected	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

Free	NULL
probe	NULL
cleaved	NULL
with	NULL
piperidine	NULL
gave	NULL
a	NULL
uniform	NULL
cleavage	NULL
of	NULL
G	NULL
residues	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
specific	NULL
interference	NULL
to	NULL
other	NULL
portions	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
AP-2	NULL
bound	NULL
specifically	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
with	NULL
a	NULL
strong	NULL
requirement	NULL
for	NULL
the	NULL
core	NULL
sequences	NULL
AGGC	NULL
found	NULL
in	NULL
this	NULL
motif	NULL
.	NULL

Comparison	NULL
of	NULL
AP-2	NULL
binding	NULL
to	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeat	NULL
and	NULL
metallothionein	NULL
enhancer	NULL
We	NULL
next	NULL
wished	NULL
to	NULL
determine	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
AP-2	NULL
protein	NULL
to	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
relative	NULL
to	NULL
that	NULL
seen	NULL
with	NULL
the	NULL
consensus	NULL
in	NULL
the	NULL
AP-2	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
metallothionein	NULL
promoter	NULL
.	NULL

Gel	NULL
retardation	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
labeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
and	NULL
either	NULL
GST	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
bacterially	NULL
produced	NULL
AP-2	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Competition	NULL
analysis	NULL
was	NULL
2576	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

AP-2	NULL
binds	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

Bacterially	NULL
produced	NULL
GST/AP-2	NULL
was	NULL
used	NULL
in	NULL
gel	NULL
regardation	NULL
assays	NULL
with	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
III	NULL
repeat	NULL
.	NULL

GST	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
GST/AP-2	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
GST/AP-2	NULL
with	NULL
a	NULL
3-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
wild-type	NULL
oligonucleotides	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
unlabeled	NULL
oligonucleotides	NULL
containing	NULL
a	NULL
mutated	NULL
A	NULL
site	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
mutated	NULL
B	NULL
site	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
mutated	NULL
C	NULL
site	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
mutated	NULL
A	NULL
and	NULL
C	NULL
sites	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
or	NULL
mutated	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
sites	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

performed	NULL
with	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
lanes	NULL
3-7	NULL
)	NULL
or	NULL
the	NULL
metallothionein	NULL
AP-2	NULL
motif	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
lanes	NULL
9-13	NULL
)	NULL
.	NULL

The	NULL
competition	NULL
analysis	NULL
with	NULL
the	NULL
unlabeled	NULL
21	NULL
bp	NULL
repeat	NULL
oligonucleotides	NULL
demonstrated	NULL
that	NULL
75	NULL
%	NULL
inhibition	NULL
of	NULL
AP-2	NULL
binding	NULL
occurred	NULL
at	NULL
a	NULL
15-fold	NULL
molar	NULL
excess	NULL
of	NULL
cold	NULL
competitor	NULL
.	NULL

Competition	NULL
with	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
metallothionein	NULL
AP-2	NULL
binding	NULL
site	NULL
demonstrated	NULL
that	NULL
75	NULL
%	NULL
inhibition	NULL
of	NULL
AP-2	NULL
binding	NULL
was	NULL
seen	NULL
with	NULL
a	NULL
3-fold	NULL
molar	NULL
excess	NULL
of	NULL
cold	NULL
competitor	NULL
.	NULL

These	NULL
results	NULL
demonstrated	NULL
that	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
AP-2	NULL
to	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
was	NULL
less	NULL
than	NULL
but	NULL
in	NULL
a	NULL
range	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
to	NULL
the	NULL
metallothionein	NULL
AP-2	NULL
binding	NULL
site	NULL
.	NULL

AP-2	NULL
excludes	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
member	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
Within	NULL
an	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeat	NULL
,	NULL
different	NULL
cellular	NULL
factors	NULL
probably	NULL
bind	NULL
to	NULL
each	NULL
of	NULL
the	NULL
three	NULL
defined	NULL
motifs	NULL
.	NULL

Therefore	NULL
it	NULL
was	NULL
important	NULL
to	NULL
determine	NULL
whether	NULL
multiple	NULL
proteins	NULL
may	NULL
bind	NULL
simultaneously	NULL
to	NULL
these	NULL
different	NULL
motifs	NULL
within	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

We	NULL
investigated	NULL
whether	NULL
AP-2	NULL
binding	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
could	NULL
prevent	NULL
members	NULL
of	NULL
the	NULL
ATF/CREB	NULL
family	NULL
such	NULL
as	NULL
CREB	NULL
(	NULL
Hoeffler	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
and	NULL
CRE-BPI1	NULL
(	NULL
Maekawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
from	NULL
binding	NULL
to	NULL
the	NULL
B	NULL
motif	NULL
.	NULL

Gel	NULL
retardation	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
either	NULL
uncleaved	NULL
or	NULL
a	NULL
thrombin	NULL
AP-2	NULL
activation	NULL
of	NULL
HTLV-I	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Methylation	NULL
interference	NULL
of	NULL
AP-2	NULL
binding	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

Either	NULL
the	NULL
non-coding	NULL
(	NULL
A	NULL
)	NULL
or	NULL
coding	NULL
(	NULL
B	NULL
)	NULL
strands	NULL
of	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
III	NULL
were	NULL
end-labeled	NULL
and	NULL
used	NULL
in	NULL
methylation	NULL
interference	NULL
.	NULL

Maxam-Gilbert	NULL
sequencing	NULL
lanes	NULL
A+G	NULL
and	NULL
C+T	NULL
,	NULL
and	NULL
methylation	NULL
interference	NULL
of	NULL
the	NULL
GST/AP-2	NULL
gel-retarded	NULL
species	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
G	NULL
residues	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
which	NULL
serve	NULL
as	NULL
contacts	NULL
with	NULL
AP-2	NULL
are	NULL
indicated	NULL
by	NULL
straight	NULL
lines	NULL
.	NULL

cleaved	NULL
truncated	NULL
AP-2	NULL
fusion	NULL
protein	NULL
designated	NULL
GST/AAP-2	NULL
and	NULL
GST/CRE-BP1	NULL
.	NULL

Only	NULL
the	NULL
results	NULL
with	NULL
the	NULL
fusion	NULL
proteins	NULL
were	NULL
shown	NULL
.	NULL

This	NULL
truncated	NULL
form	NULL
of	NULL
AP-2	NULL
which	NULL
had	NULL
binding	NULL
and	NULL
dimerization	NULL
properties	NULL
that	NULL
were	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
native	NULL
AP-2	NULL
(	NULL
Williams	NULL
and	NULL
Tjian	NULL
,	NULL
1992a	NULL
,	NULL
b	NULL
)	NULL
was	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
to	NULL
separate	NULL
better	NULL
the	NULL
AP2	NULL
and	NULL
CRE-BPI1	NULL
species	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
labeled	NULL
probe	NULL
used	NULL
in	NULL
the	NULL
gel	NULL
retardation	NULL
resulted	NULL
in	NULL
80-90	NULL
%	NULL
saturation	NULL
so	NULL
that	NULL
formation	NULL
of	NULL
DNA-protein	NULL
complexes	NULL
composed	NULL
of	NULL
both	NULL
AP-2	NULL
and	NULL
CRE-BPI	NULL
would	NULL
be	NULL
favored	NULL
.	NULL

Gel	NULL
retardation	NULL
demonstrated	NULL
that	NULL
AAP-2	NULL
and	NULL
CRE-BPI1	NULL
were	NULL
each	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

When	NULL
equimolar	NULL
amounts	NULL
of	NULL
both	NULL
proteins	NULL
were	NULL
added	NULL
simultaneously	NULL
to	NULL
the	NULL
labeled	NULL
oligonucleotides	NULL
,	NULL
both	NULL
AAP-2	NULL
and	NULL
CRE-BPI	NULL
bound	NULL
individually	NULL
to	NULL
the	NULL
oligonucleotides	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

No	NULL
slower	NULL
mobility	NULL
species	NULL
that	NULL
would	NULL
indicate	NULL
the	NULL
binding	NULL
of	NULL
both	NULL
proteins	NULL
to	NULL
the	NULL
same	NULL
probe	NULL
was	NULL
detected	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
AP-2	NULL
and	NULL
CRE-BP1	NULL
could	NULL
exclude	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
other	NULL
protein	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

Mutant	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
oligonucleotides	NULL
in	NULL
either	NULL
the	NULL
B	NULL
motif	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lanes	NULL
5-8	NULL
)	NULL
or	NULL
the	NULL
A	NULL
motif	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lanes	NULL
9-12	NULL
)	NULL
were	NULL
also	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
B	NULL
motif	NULL
did	NULL
not	NULL
alter	NULL
AAP-2	NULL
binding	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
and	NULL
8	NULL
)	NULL
but	NULL
completely	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
CRE-BPI	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
mutations	NULL
of	NULL
the	NULL
A	NULL
motif	NULL
eliminated	NULL
AAP-2	NULL
binding	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
CRE-BP	NULL
1	NULL
binding	NULL
(	NULL
Figure	NULL
8	NULL
,	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicated	NULL
that	NULL
AP-2	NULL
and	NULL
CRE-BPI1	NULL
bound	NULL
indepen-	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Binding	NULL
affinity	NULL
of	NULL
AP-2	NULL
to	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
III	NULL
repeat	NULL
.	NULL

Labeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
with	NULL
GST	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
GST/AP-2	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
.	NULL

For	NULL
competition	NULL
analysis	NULL
,	NULL
increasing	NULL
amounts	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
(	NULL
lanes	NULL
3-7	NULL
)	NULL
or	NULL
the	NULL
metallothionein	NULL
AP-2-binding	NULL
site	NULL
(	NULL
lanes	NULL
9-13	NULL
)	NULL
in	NULL
either	NULL
a	NULL
10-fold	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
)	NULL
,	NULL
20-fold	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
10	NULL
)	NULL
,	NULL
50-fold	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
11	NULL
)	NULL
,	NULL
100-fold	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
12	NULL
)	NULL
or	NULL
200-fold	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
13	NULL
)	NULL
molar	NULL
excess	NULL
were	NULL
used	NULL
.	NULL

dently	NULL
to	NULL
different	NULL
portions	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
and	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
one	NULL
protein	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
excluded	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
other	NULL
protein	NULL
.	NULL

2577	NULL
C.	NULL
Muchardt	NULL
et	NULL
al	NULL
.	NULL

Fig	NULL
.	NULL

8	NULL
.	NULL

AP-2	NULL
excludes	NULL
CRE-BP1	NULL
binding	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

Labeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
,	NULL
21	NULL
bp	NULL
III	NULL
with	NULL
a	NULL
mutated	NULL
B	NULL
site	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
or	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
with	NULL
a	NULL
mutated	NULL
A	NULL
site	NULL
(	NULL
lanes	NULL
9-12	NULL
)	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
with	NULL
GST	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
5	NULL
and	NULL
9	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
truncated	NULL
GST/AAP-2	NULL
protein	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
6	NULL
and	NULL
10	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
GST/CRE-BPI	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
7	NULL
and	NULL
11	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
GST/CRE-BP1	NULL
and	NULL
truncated	NULL
GST/AP-2	NULL
proteins	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
8	NULL
and	NULL
12	NULL
)	NULL
.	NULL

The	NULL
position	NULL
of	NULL
mutations	NULL
in	NULL
either	NULL
the	NULL
A	NULL
or	NULL
B	NULL
motifs	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
is	NULL
also	NULL
indicated	NULL
.	NULL

AP-2	NULL
activates	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
Since	NULL
we	NULL
demonstrated	NULL
that	NULL
AP-2	NULL
bound	NULL
specifically	NULL
to	NULL
each	NULL
of	NULL
the	NULL
HTLV-I	NULL
21	NULL
bp	NULL
repeats	NULL
,	NULL
we	NULL
next	NULL
determined	NULL
the	NULL
role	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
in	NULL
regulating	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
in	NULL
T-lymphocytes	NULL
.	NULL

Each	NULL
transfection	NULL
was	NULL
repeated	NULL
three	NULL
times	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

Transfection	NULL
of	NULL
an	NULL
AP-2	NULL
expression	NULL
vector	NULL
and	NULL
an	NULL
HTLV-I	NULL
LTR	NULL
CAT	NULL
construct	NULL
into	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
2-	NULL
to	NULL
3-fold	NULL
stimulation	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
(	NULL
Figure	NULL
9	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
tax	NULL
with	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
CAT	NULL
construct	NULL
into	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
6-	NULL
to	NULL
8-fold	NULL
stimulation	NULL
of	NULL
gene	NULL
expression	NULL
(	NULL
Figure	NULL
9A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
A	NULL
sites	NULL
in	NULL
each	NULL
of	NULL
the	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
in	NULL
the	NULL
HTLV-I	NULL
CAT	NULL
construct	NULL
eliminated	NULL
activation	NULL
by	NULL
AP-2	NULL
and	NULL
resulted	NULL
in	NULL
only	NULL
slight	NULL
stimulation	NULL
by	NULL
tax	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
AP-2	NULL
weakly	NULL
stimulated	NULL
gene	NULL
expression	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
A	NULL
site	NULL
decreased	NULL
both	NULL
AP-2	NULL
and	NULL
tax	NULL
activation	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
.	NULL

Similar	NULL
transfections	NULL
were	NULL
performed	NULL
with	NULL
PHA	NULL
,	NULL
ionomycin	NULL
and	NULL
PMA	NULL
-stimulated	NULL
Jurkat	NULL
cells	NULL
.	NULL

AP-2	NULL
activated	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
CAT	NULL
gene	NULL
expression	NULL
4-	NULL
to	NULL
5-fold	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Figure	NULL
9B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
while	NULL
tax	NULL
resulted	NULL
in	NULL
a	NULL
20-fold	NULL
stimulation	NULL
of	NULL
this	NULL
construct	NULL
(	NULL
Figure	NULL
9B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Mutations	NULL
of	NULL
each	NULL
A	NULL
site	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
eliminated	NULL
AP-2	NULL
activation	NULL
and	NULL
decreased	NULL
tax	NULL
activation	NULL
to	NULL
3-fold	NULL
(	NULL
Figure	NULL
9B	NULL
,	NULL
Lanes	NULL
4-6	NULL
)	NULL
.	NULL

Four-	NULL
to	NULL
S-fold	NULL
activation	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
by	NULL
AP-2	NULL
was	NULL
also	NULL
seen	NULL
when	NULL
these	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
HUT78	NULL
(	NULL
Figure	NULL
9C	NULL
)	NULL
and	NULL
SLB	NULL
cells	NULL
2578	NULL
Fig	NULL
.	NULL

9	NULL
.	NULL

AP-2	NULL
activates	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
.	NULL

A	NULL
wild-type	NULL
HTLV	NULL
LTR-I	NULL
CAT	NULL
construct	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
or	NULL
a	NULL
similar	NULL
construct	NULL
mutated	NULL
in	NULL
the	NULL
A	NULL
site	NULL
of	NULL
all	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
(	NULL
lanes	NULL
4-6	NULL
)	NULL
were	NULL
cotransfected	NULL
into	NULL
either	NULL
nonstimulated	NULL
(	NULL
A	NULL
)	NULL
or	NULL
TPA	NULL
,	NULL
PHA	NULL
and	NULL
ionomycin	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
with	NULL
either	NULL
expression	NULL
vector	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
an	NULL
AP-2	NULL
expression	NULL
construct	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
or	NULL
2.5	NULL
ug	NULL
of	NULL
a	NULL
tax	NULL
expression	NULL
construct	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
HUT78	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
wild-type	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
or	NULL
mutated	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
HTLV-I	NULL
constructs	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
4	NULL
contain	NULL
no	NULL
AP-2	NULL
expression	NULL
vector	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
contain	NULL
1	NULL
4g	NULL
of	NULL
this	NULL
expression	NULL
vector	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
contain	NULL
3	NULL
ug	NULL
and	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
contain	NULL
2.5	NULL
ag	NULL
of	NULL
a	NULL
tax	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
percent	NULL
CAT	NULL
conversion	NULL
for	NULL
each	NULL
sample	NULL
was	NULL
calculated	NULL
.	NULL

(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
both	NULL
AP-2	NULL
and	NULL
tax	NULL
were	NULL
capable	NULL
of	NULL
significant	NULL
activation	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
in	NULL
T-lymphocytes	NULL
.	NULL

Next	NULL
we	NULL
defined	NULL
the	NULL
number	NULL
of	NULL
21	NULL
bp	NULL
repeats	NULL
required	NULL
for	NULL
activation	NULL
by	NULL
AP-2	NULL
and	NULL
tax	NULL
.	NULL

A	NULL
schematic	NULL
of	NULL
the	NULL
constructs	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
is	NULL
shown	NULL
in	NULL
Figure	NULL
10	NULL
.	NULL

All	NULL
transfections	NULL
were	NULL
performed	NULL
in	NULL
four	NULL
independent	NULL
experiments	NULL
on	NULL
both	NULL
Jurkat	NULL
and	NULL
HepG2	NULL
cells	NULL
,	NULL
a	NULL
cell	NULL
line	NULL
which	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
contain	NULL
non-detectable	NULL
levels	NULL
of	NULL
AP-2	NULL
(	NULL
Williams	NULL
eral	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
result	NULL
obtained	NULL
for	NULL
each	NULL
construct	NULL
is	NULL
given	NULL
in	NULL
fold	NULL
activation	NULL
.	NULL

Significant	NULL
activation	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
by	NULL
AP-2	NULL
expression	NULL
vectors	NULL
required	NULL
at	NULL
least	NULL
two	NULL
21	NULL
bp	NULL
repeats	NULL
(	NULL
Figure	NULL
10	NULL
,	NULL
lines	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

HTLV-I	NULL
CAT	NULL
constructs	NULL
containing	NULL
either	NULL
21	NULL
bp	NULL
repeats	NULL
II	NULL
and	NULL
III	NULL
or	NULL
I	NULL
and	NULL
II	NULL
gave	NULL
levels	NULL
of	NULL
gene	NULL
expression	NULL
with	NULL
AP-2	NULL
that	NULL
were	NULL
slightly	NULL
decreased	NULL
as	NULL
compared	NULL
with	NULL
that	NULL
seen	NULL
with	NULL
all	NULL
three	NULL
21	NULL
bp	NULL
repeats	NULL
(	NULL
Figure	NULL
10	NULL
,	NULL
lines	NULL
1-3	NULL
)	NULL
.	NULL

All	NULL
these	NULL
AP-2	NULL
activation	NULL
of	NULL
HTLV-I	NULL
FOLD	NULL
ACTIVATION	NULL
APZ	NULL
Tax	NULL
TATA	NULL
V	NULL
,	NULL
3.1	NULL
7.2	NULL
y	NULL
\_	NULL
2.3	NULL
6.0	NULL
|__	NULL
BP	NULL
1.0	NULL
4.0	NULL
I	NULL
II	NULL
Ets	NULL
IH	NULL
1	NULL
.	NULL

Flaâ€”ML	NULL
4.1	NULL
9.5	NULL
-323	NULL
2	NULL
.	NULL

F	NULL
I	NULL
1	NULL
I	NULL
1	NULL
-210	NULL
3	NULL
_C	NULL
]	NULL
[	NULL
~~	NULL
-323	NULL
-120	NULL
-55	NULL
4	NULL
I	NULL
I	NULL
1	NULL
*	NULL
-167	NULL
5	NULL
.	NULL

A8	NULL
,	NULL
1.0	NULL
1.0	NULL
-210	NULL
-120	NULL
7	NULL
,	NULL
PEAâ€”L	NULL
1.0	NULL
1.0	NULL
-323	NULL
-210	NULL
Fig	NULL
.	NULL

10	NULL
.	NULL

Activation	NULL
of	NULL
HTLV-I	NULL
mutants	NULL
by	NULL
AP-2	NULL
and	NULL
tax	NULL
.	NULL

A	NULL
variety	NULL
of	NULL
truncated	NULL
HTLV-I	NULL
LTR	NULL
constructs	NULL
were	NULL
cotransfected	NULL
into	NULL
Hep	NULL
G2	NULL
cells	NULL
with	NULL
either	NULL
an	NULL
AP-2	NULL
expression	NULL
vector	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
,	NULL
a	NULL
tax	NULL
expression	NULL
vector	NULL
(	NULL
2.5	NULL
ug	NULL
)	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
these	NULL
factors	NULL
.	NULL

The	NULL
final	NULL
concentration	NULL
of	NULL
expression	NULL
vector	NULL
in	NULL
each	NULL
transfection	NULL
was	NULL
kept	NULL
constant	NULL
at	NULL
10	NULL
ug	NULL
by	NULL
adding	NULL
RSV	NULL
-globin	NULL
.	NULL

The	NULL
results	NULL
are	NULL
the	NULL
summary	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
and	NULL
the	NULL
results	NULL
are	NULL
expressed	NULL
in	NULL
fold	NULL
of	NULL
activation	NULL
of	NULL
each	NULL
construct	NULL
by	NULL
AP-2	NULL
and	NULL
tax	NULL
.	NULL

constructs	NULL
were	NULL
also	NULL
strongly	NULL
activated	NULL
by	NULL
tax	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
by	NULL
Fujisawa	NULL
ert	NULL
al	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Constructs	NULL
containing	NULL
only	NULL
one	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
were	NULL
not	NULL
significantly	NULL
activated	NULL
by	NULL
AP-2	NULL
(	NULL
Figure	NULL
10	NULL
,	NULL
lines	NULL
4-7	NULL
)	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
also	NULL
poorly	NULL
activated	NULL
by	NULL
tax	NULL
except	NULL
for	NULL
one	NULL
construct	NULL
which	NULL
contained	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
and	NULL
an	NULL
element	NULL
which	NULL
binds	NULL
both	NULL
the	NULL
ets	NULL
(	NULL
Bosselut	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Gitlin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
and	NULL
SPI	NULL
(	NULL
Nyborg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
proteins	NULL
(	NULL
Figure	NULL
10	NULL
,	NULL
line	NULL
4	NULL
)	NULL
.	NULL

Discussion	NULL
Multiple	NULL
regions	NULL
in	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
are	NULL
critical	NULL
for	NULL
modulating	NULL
gene	NULL
expression	NULL
(	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
,	NULL
1989	NULL
;	NULL
Paskalis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Shimotohno	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Brady	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Rosen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Bosselut	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

These	NULL
regulatory	NULL
regions	NULL
serve	NULL
as	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
proteins	NULL
(	NULL
Altman	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Jeang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Nyborg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
,	NULL
1990	NULL
;	NULL
Tan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Bosselut	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
BÃ©raud	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
transactivator	NULL
protein	NULL
,	NULL
tax	NULL
,	NULL
is	NULL
also	NULL
required	NULL
for	NULL
high	NULL
levels	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
(	NULL
Sodroski	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Felber	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Fujisawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Smith	NULL
and	NULL
Greene	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-2	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
.	NULL

Fractionation	NULL
of	NULL
cellular	NULL
extracts	NULL
reveals	NULL
that	NULL
multiple	NULL
factors	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
(	NULL
Altman	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Jeang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Nyborg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
,	NULL
1990	NULL
;	NULL
Tan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Bosselut	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

These	NULL
factors	NULL
appear	NULL
in	NULL
some	NULL
instances	NULL
to	NULL
have	NULL
cell-type	NULL
specificity	NULL
though	NULL
most	NULL
factors	NULL
have	NULL
not	NULL
been	NULL
completely	NULL
characterized	NULL
(	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

One	NULL
study	NULL
reports	NULL
that	NULL
oligonucleotide	NULL
affinity	NULL
column	NULL
purified	NULL
AP-2	NULL
from	NULL
HeLa	NULL
cells	NULL
binds	NULL
to	NULL
a	NULL
region	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
which	NULL
overlaps	NULL
each	NULL
of	NULL
the	NULL
21	NULL
bp	NULL
repeats	NULL
,	NULL
but	NULL
AP-2	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
SLB	NULL
cells	NULL
using	NULL
DNase	NULL
I	NULL
footprinting	NULL
assays	NULL
(	NULL
Nyborg	NULL
and	NULL
Dynan	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
detected	NULL
AP-2	NULL
RNA	NULL
and	NULL
binding	NULL
activity	NULL
in	NULL
several	NULL
T-lymphocyte	NULL
cell	NULL
lines	NULL
using	NULL
PCR	NULL
and	NULL
gel	NULL
retardation	NULL
assays	NULL
.	NULL

The	NULL
level	NULL
of	NULL
AP-2	NULL
RNA	NULL
and	NULL
protein	NULL
in	NULL
HeLa	NULL
cells	NULL
is	NULL
also	NULL
relatively	NULL
low	NULL
since	NULL
AP-2	NULL
expression	NULL
vectors	NULL
activate	NULL
constructs	NULL
with	NULL
AP-2	NULL
binding	NULL
sites	NULL
in	NULL
transfection	NULL
assays	NULL
performed	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
Williams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
,	NULL
using	NULL
Agt11	NULL
expression	NULL
cloning	NULL
with	NULL
oligonucleotides	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
B	NULL
motif	NULL
,	NULL
demonstrate	NULL
that	NULL
multiple	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
bind	NULL
to	NULL
this	NULL
region	NULL
(	NULL
Hai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Tsujimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Yoshimura	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Which	NULL
if	NULL
any	NULL
of	NULL
these	NULL
factors	NULL
is/are	NULL
responsible	NULL
for	NULL
tax	NULL
activation	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
demonstrated	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
constructs	NULL
containing	NULL
isolated	NULL
CREB/ATF	NULL
sites	NULL
are	NULL
not	NULL
inducible	NULL
by	NULL
tax	NULL
,	NULL
suggesting	NULL
that	NULL
either	NULL
the	NULL
position	NULL
of	NULL
these	NULL
2579	NULL
C.Muchardt	NULL
et	NULL
af	NULL
.	NULL

sites	NULL
in	NULL
a	NULL
specific	NULL
promoter	NULL
or	NULL
proteins	NULL
binding	NULL
to	NULL
overlapping	NULL
motifs	NULL
are	NULL
critical	NULL
for	NULL
tax	NULL
activation	NULL
(	NULL
Montagne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
both	NULL
the	NULL
A	NULL
and	NULL
C	NULL
sites	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
are	NULL
critical	NULL
for	NULL
tax	NULL
activation	NULL
suggests	NULL
that	NULL
multiple	NULL
factors	NULL
may	NULL
be	NULL
required	NULL
for	NULL
tax	NULL
activation	NULL
.	NULL

Since	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
has	NULL
strong	NULL
homology	NULL
with	NULL
AP-2	NULL
binding	NULL
sites	NULL
found	NULL
in	NULL
the	NULL
SV40	NULL
and	NULL
metallothionein	NULL
promoters	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
AP-2	NULL
could	NULL
bind	NULL
and	NULL
activate	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
21	NULL
bp	NULL
repeats	NULL
.	NULL

AP-2	NULL
RNA	NULL
is	NULL
expressed	NULL
in	NULL
T-lymphocytes	NULL
and	NULL
a	NULL
cellular	NULL
protein	NULL
of	NULL
similar	NULL
molecular	NULL
weight	NULL
and	NULL
mobility	NULL
to	NULL
AP-2	NULL
binds	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

To	NULL
investigate	NULL
AP-2	NULL
binding	NULL
to	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
further	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
protein	NULL
expressed	NULL
from	NULL
an	NULL
AP-2	NULL
cDNA	NULL
binds	NULL
specifically	NULL
and	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
the	NULL
A	NULL
motif	NULL
in	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
AP-2	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
excludes	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
member	NULL
of	NULL
the	NULL
ATF/CREB	NULL
family	NULL
,	NULL
CRE-BP1	NULL
(	NULL
Maekawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
to	NULL
an	NULL
adjacent	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
B	NULL
motif	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
AP-2	NULL
can	NULL
activate	NULL
expression	NULL
of	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
gene	NULL
in	NULL
both	NULL
T-lymphocytes	NULL
and	NULL
other	NULL
cell	NULL
lines	NULL
.	NULL

Thus	NULL
AP-2	NULL
may	NULL
be	NULL
important	NULL
in	NULL
regulating	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
during	NULL
infection	NULL
of	NULL
both	NULL
lymphoid	NULL
and	NULL
non-lymphoid	NULL
cells	NULL
(	NULL
Clapham	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
.	NULL

AP-2	NULL
binds	NULL
and	NULL
activates	NULL
gene	NULL
expression	NULL
from	NULL
other	NULL
viral	NULL
promoters	NULL
,	NULL
including	NULL
SV40	NULL
(	NULL
Mitchell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Williams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
and	NULL
hepatitis	NULL
B	NULL
(	NULL
Seto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Within	NULL
different	NULL
viral	NULL
and	NULL
cellular	NULL
promoters	NULL
there	NULL
appears	NULL
to	NULL
be	NULL
marked	NULL
degeneracy	NULL
of	NULL
the	NULL
AP-2	NULL
consensus	NULL
binding	NULL
sequences	NULL
.	NULL

The	NULL
binding	NULL
domain	NULL
of	NULL
AP-2	NULL
has	NULL
no	NULL
detectable	NULL
homology	NULL
with	NULL
other	NULL
well	NULL
described	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
AP-2	NULL
contains	NULL
a	NULL
carboxyl-terminal	NULL
dimerization	NULL
domain	NULL
and	NULL
an	NULL
amino-terminal	NULL
proline-rich	NULL
activating	NULL
domain	NULL
(	NULL
Williams	NULL
and	NULL
Tjian	NULL
,	NULL
1991a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

UV	NULL
crosslinking	NULL
experiments	NULL
indicate	NULL
that	NULL
AP-2	NULL
binds	NULL
to	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
as	NULL
a	NULL
dimer	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
its	NULL
binding	NULL
to	NULL
other	NULL
promoters	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
Williams	NULL
and	NULL
Tjian	NULL
,	NULL
1991a	NULL
,	NULL
b	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
AP-2	NULL
excludes	NULL
binding	NULL
of	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
family	NULL
to	NULL
the	NULL
B	NULL
motif	NULL
suggests	NULL
that	NULL
different	NULL
factors	NULL
may	NULL
compete	NULL
for	NULL
the	NULL
binding	NULL
to	NULL
the	NULL
21	NULL
bp	NULL
repeat	NULL
resulting	NULL
in	NULL
different	NULL
patterns	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

Since	NULL
the	NULL
activity	NULL
of	NULL
AP-2	NULL
is	NULL
regulated	NULL
by	NULL
both	NULL
phorbol	NULL
esters	NULL
and	NULL
cyclic	NULL
AMP	NULL
(	NULL
Imagawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Luscher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
AP-2	NULL
may	NULL
mediate	NULL
expression	NULL
of	NULL
HTLV-I	NULL
by	NULL
various	NULL
stimuli	NULL
which	NULL
affect	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
(	NULL
Poteat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Tan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989b	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
may	NULL
be	NULL
regulated	NULL
by	NULL
cellular	NULL
factors	NULL
such	NULL
as	NULL
the	NULL
recently	NULL
described	NULL
HEBI1	NULL
(	NULL
BÃ©raud	NULL
eral	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
which	NULL
potentially	NULL
activate	NULL
gene	NULL
expression	NULL
in	NULL
a	NULL
tax-dependent	NULL
manner	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
other	NULL
factors	NULL
which	NULL
function	NULL
independent	NULL
of	NULL
tax	NULL
.	NULL

The	NULL
role	NULL
of	NULL
tax	NULL
in	NULL
modulating	NULL
AP-2	NULL
activation	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
is	NULL
not	NULL
addressed	NULL
in	NULL
this	NULL
study	NULL
.	NULL

However	NULL
,	NULL
experiments	NULL
suggest	NULL
that	NULL
tax	NULL
inhibits	NULL
AP-2	NULL
activation	NULL
of	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
by	NULL
direct	NULL
interaction	NULL
of	NULL
tax	NULL
with	NULL
AP-2	NULL
.	NULL

This	NULL
situation	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
interaction	NULL
of	NULL
SV40	NULL
T	NULL
antigen	NULL
with	NULL
AP-2	NULL
which	NULL
results	NULL
in	NULL
inhibition	NULL
of	NULL
SV40	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
tax	NULL
has	NULL
also	NULL
been	NULL
demonstrated	NULL
to	NULL
regulate	NULL
negatively	NULL
DNA	NULL
polymerase	NULL
B	NULL
which	NULL
contains	NULL
potential	NULL
AP-2	NULL
binding	NULL
sites	NULL
(	NULL
Mitchell	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Jeang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
one	NULL
possible	NULL
mechanism	NULL
of	NULL
tax	NULL
regulation	NULL
may	NULL
be	NULL
to	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
one	NULL
group	NULL
of	NULL
cellular	NULL
transcription	NULL
factors	NULL
and	NULL
allow	NULL
the	NULL
binding	NULL
of	NULL
different	NULL
factors	NULL
which	NULL
may	NULL
result	NULL
in	NULL
altered	NULL
patterns	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

Further	NULL
studies	NULL
will	NULL
be	NULL
required	NULL
to	NULL
define	NULL
the	NULL
role	NULL
of	NULL
AP-2	NULL
2580	NULL
in	NULL
activating	NULL
HTLV-I	NULL
gene	NULL
expression	NULL
in	NULL
both	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
tax	NULL
and	NULL
its	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
HTLV-I	NULL
infection	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Plasmid	NULL
constructs	NULL
A	NULL
HeLa	NULL
cDNA	NULL
library	NULL
cloned	NULL
into	NULL
AZAP	NULL
was	NULL
screened	NULL
with	NULL
3Omer	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
both	NULL
the	NULL
amino-	NULL
and	NULL
carboxyl-termini	NULL
of	NULL
the	NULL
AP-2	NULL
coding	NULL
sequences	NULL
.	NULL

An	NULL
AP-2	NULL
cDNA	NULL
spanning	NULL
the	NULL
entire	NULL
AP-2	NULL
coding	NULL
region	NULL
extending	NULL
from	NULL
nt	NULL
8	NULL
to	NULL
1621	NULL
was	NULL
isolated	NULL
(	NULL
Williams	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

This	NULL
cDNA	NULL
was	NULL
cloned	NULL
in	NULL
pGEM2	NULL
,	NULL
downstream	NULL
of	NULL
an	NULL
SP6	NULL
promoter	NULL
for	NULL
in	NULL
vitro	NULL
expression	NULL
.	NULL

A	NULL
BamHI	NULL
site	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
amino-terminus	NULL
of	NULL
AP-2	NULL
and	NULL
a	NULL
BamHI-EcoRI	NULL
fragment	NULL
from	NULL
this	NULL
construct	NULL
was	NULL
cloned	NULL
into	NULL
pGEX-2T	NULL
(	NULL
Pharmacia	NULL
)	NULL
for	NULL
bacterial	NULL
expression	NULL
(	NULL
Smith	NULL
and	NULL
Johnson	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

A	NULL
truncation	NULL
of	NULL
AP-2	NULL
spanning	NULL
amino	NULL
acids	NULL
165-437	NULL
was	NULL
also	NULL
cloned	NULL
into	NULL
the	NULL
Smal	NULL
and	NULL
EcoRI	NULL
sites	NULL
of	NULL
pGEX-2T	NULL
for	NULL
bacterial	NULL
expression	NULL
.	NULL

A	NULL
cDNA	NULL
containing	NULL
the	NULL
complete	NULL
coding	NULL
sequence	NULL
of	NULL
CRE-BPI	NULL
(	NULL
Maekawa	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
was	NULL
isolated	NULL
from	NULL
a	NULL
Agt11	NULL
library	NULL
.	NULL

A	NULL
BamHI	NULL
site	NULL
was	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
ATG	NULL
using	NULL
PCR	NULL
and	NULL
a	NULL
Bam-EcoRI	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
pGEX-2T	NULL
.	NULL

For	NULL
transfection	NULL
experiments	NULL
,	NULL
an	NULL
EcoRI	NULL
fragment	NULL
spanning	NULL
the	NULL
AP-2	NULL
cDNA	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
pDP18	NULL
(	NULL
Garcia	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

A	NULL
tax	NULL
cDNA	NULL
(	NULL
Wano	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
pDP18	NULL
.	NULL

PCR	NULL
reactions	NULL
AP-2	NULL
cDNA	NULL
was	NULL
hexamer	NULL
primed	NULL
from	NULL
10	NULL
pg	NULL
of	NULL
total	NULL
Jurkat	NULL
E	NULL
cDNA	NULL
using	NULL
reagents	NULL
and	NULL
conditions	NULL
prescribed	NULL
in	NULL
a	NULL
Promega	NULL
Riboclone	NULL
cDNA	NULL
synthesis	NULL
kit	NULL
.	NULL

A	NULL
mock	NULL
cDNA	NULL
synthesis	NULL
was	NULL
performed	NULL
by	NULL
deleting	NULL
AMV	NULL
reverse	NULL
transcriptase	NULL
from	NULL
the	NULL
reaction	NULL
mix	NULL
and	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
template	NULL
for	NULL
subsequent	NULL
PCR	NULL
analysis	NULL
.	NULL

One-tenth	NULL
of	NULL
the	NULL
hexamer	NULL
primed	NULL
cDNA	NULL
was	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
PCR	NULL
which	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
DNA	NULL
thermal	NULL
cycler	NULL
using	NULL
reagents	NULL
from	NULL
a	NULL
GeneAmp	NULL
Kit	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
heated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
94Â°C	NULL
and	NULL
was	NULL
subsequently	NULL
incubated	NULL
for	NULL
40	NULL
cycles	NULL
of	NULL
PCR	NULL
(	NULL
55Â°C	NULL
,	NULL
1	NULL
min	NULL
;	NULL
72Â°C	NULL
,	NULL
1	NULL
min	NULL
;	NULL
94Â°C	NULL
,	NULL
1	NULL
min	NULL
)	NULL
.	NULL

2	NULL
al	NULL
of	NULL
the	NULL
reaction	NULL
was	NULL
reamplified	NULL
for	NULL
40	NULL
cycles	NULL
using	NULL
a	NULL
nested	NULL
antisense	NULL
primer	NULL
.	NULL

25mer	NULL
oligonucleotide	NULL
primers	NULL
used	NULL
for	NULL
PCR	NULL
contained	NULL
sequences	NULL
corresponding	NULL
to	NULL
the	NULL
following	NULL
positions	NULL
in	NULL
the	NULL
AP-2	NULL
cDNA	NULL
(	NULL
Williams	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
:	NULL
sense	NULL
primer	NULL
(	NULL
nt	NULL
63-87	NULL
)	NULL
,	NULL
antisense	NULL
primer	NULL
(	NULL
nt	NULL
701-725	NULL
)	NULL
,	NULL
5-GAGGGAGCGAGAGGCGACCCG-GAACT-3	NULL
'	NULL
;	NULL
antisense	NULL
nested	NULL
primer	NULL
(	NULL
nt	NULL
599-623	NULL
)	NULL
,	NULL
5-GCTGTTGGAC-TTGGACAGGGACACG-3	NULL
'	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
electroeluted	NULL
from	NULL
the	NULL
polyacrylamide	NULL
,	NULL
phosphorylated	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
cloned	NULL
into	NULL
pUC	NULL
19	NULL
for	NULL
DNA	NULL
sequencing	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
and	NULL
translation	NULL
For	NULL
in	NULL
vitro	NULL
translation	NULL
,	NULL
AP-2/pGEM2	NULL
was	NULL
linearized	NULL
with	NULL
HindIII	NULL
and	NULL
transcribed	NULL
in	NULL
vitro	NULL
using	NULL
a	NULL
commercial	NULL
kit	NULL
for	NULL
RNA	NULL
synthesis	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
translated	NULL
in	NULL
vitro	NULL
with	NULL
micrococcal	NULL
nuclease	NULL
treated	NULL
rabbit	NULL
reticulocyte	NULL
lysate	NULL
in	NULL
50	NULL
pl	NULL
reaction	NULL
volume	NULL
,	NULL
as	NULL
directed	NULL
by	NULL
the	NULL
supplier	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

For	NULL
analysis	NULL
of	NULL
the	NULL
translation	NULL
products	NULL
,	NULL
proteins	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
Â°S	NULL
)	NULL
methionine	NULL
and	NULL
a	NULL
5	NULL
gl	NULL
aliquot	NULL
was	NULL
run	NULL
on	NULL
an	NULL
8	NULL
%	NULL
SDS-poly-acrylamide	NULL
gel	NULL
.	NULL

After	NULL
electrophoresis	NULL
,	NULL
the	NULL
gel	NULL
was	NULL
dried	NULL
and	NULL
subject	NULL
to	NULL
autoradiography	NULL
.	NULL

Bacterial	NULL
expression	NULL
of	NULL
AP-2	NULL
and	NULL
CRE-BP1	NULL
CRE-BPUpGEX-2T	NULL
,	NULL
AP-2/pGEM-2T	NULL
and	NULL
AAP-2/pGEX-2T	NULL
constructs	NULL
and	NULL
a	NULL
control	NULL
pGEX-2T	NULL
without	NULL
insert	NULL
were	NULL
transformed	NULL
into	NULL
Â£	NULL
.	NULL

coli	NULL
strain	NULL
JM	NULL
109	NULL
.	NULL

500	NULL
ml	NULL
cultures	NULL
of	NULL
E.coli	NULL
were	NULL
grown	NULL
to	NULL
an	NULL
of	NULL
0.7-0.9	NULL
and	NULL
induced	NULL
with	NULL
0.4	NULL
mM	NULL
IPTG	NULL
for	NULL
3	NULL
h.	NULL
Cells	NULL
were	NULL
pelleted	NULL
and	NULL
resuspended	NULL
in	NULL
10	NULL
ml	NULL
PBS	NULL
with	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
mildly	NULL
sonicated	NULL
,	NULL
debris	NULL
was	NULL
pelleted	NULL
and	NULL
supernatant	NULL
incubated	NULL
with	NULL
1	NULL
ml	NULL
glutathione-Sepharose	NULL
for	NULL
90	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
then	NULL
washed	NULL
five	NULL
times	NULL
with	NULL
10	NULL
ml	NULL
of	NULL
PBS	NULL
.	NULL

Elution	NULL
was	NULL
done	NULL
in	NULL
3	NULL
ml	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
10	NULL
mM	NULL
glutathione	NULL
incubated	NULL
for	NULL
90	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

Protein	NULL
was	NULL
dialyzed	NULL
against	NULL
protein	NULL
storage	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
then	NULL
against	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
.	NULL

Gel	NULL
retardation	NULL
analysis	NULL
For	NULL
gel	NULL
retardation	NULL
analysis	NULL
1-2	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
(	NULL
Dignam	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
prepared	NULL
from	NULL
SLB	NULL
,	NULL
Jurkat	NULL
or	NULL
HeLa	NULL
cell	NULL
lines	NULL
was	NULL
used	NULL
.	NULL

Gel	NULL
retardation	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
AP-2	NULL
was	NULL
done	NULL
with	NULL
1	NULL
al	NULL
of	NULL
a	NULL
50	NULL
ul	NULL
reaction	NULL
.	NULL

When	NULL
bacterially	NULL
produced	NULL
AP-2	NULL
(	NULL
Williams	NULL
er	NULL
a/	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
or	NULL
CRE-BPI	NULL
(	NULL
Maekawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
proteins	NULL
(	NULL
either	NULL
fused	NULL
to	NULL
glutathione-S-transferase	NULL
or	NULL
cleaved	NULL
with	NULL
thrombin	NULL
)	NULL
were	NULL
used	NULL
,	NULL
50-100	NULL
ng	NULL
of	NULL
extract	NULL
was	NULL
added	NULL
to	NULL
each	NULL
reaction	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
BSA	NULL
50	NULL
ug/ml	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
)	NULL
for	NULL
10	NULL
min	NULL
.	NULL

When	NULL
competition	NULL
was	NULL
performed	NULL
,	NULL
the	NULL
proteins	NULL
were	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
10	NULL
min	NULL
with	NULL
50	NULL
ng	NULL
cold	NULL
oligonucleotide	NULL
unless	NULL
otherwise	NULL
indicated	NULL
.	NULL

The	NULL
labeled	NULL
probe	NULL
(	NULL
50	NULL
000	NULL
c.p.m	NULL
.	NULL
)	NULL

was	NULL
added	NULL
to	NULL
the	NULL
mixture	NULL
and	NULL
after	NULL
20	NULL
min	NULL
,	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
electrophoresed	NULL
in	NULL
0.25	NULL
x	NULL
TBE	NULL
(	NULL
1	NULL
x	NULL
TBE	NULL
is	NULL
89	NULL
mM	NULL
Tris/89	NULL
mM	NULL
borate	NULL
pH	NULL
8.3	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
used	NULL
had	NULL
the	NULL
following	NULL
sequences	NULL
:	NULL
21	NULL
bp	NULL
repeat	NULL
I	NULL
,	NULL
5-CCAGACTAAGGCTCTGACGTCTCCCCCC-CGGA-3	NULL
'	NULL
;	NULL
21	NULL
bp	NULL
repeat	NULL
II	NULL
,	NULL
5-CTCGGGCTAGGCCCTGACGTG-TCCCCCTGAA-3	NULL
'	NULL
;	NULL
21	NULL
bp	NULL
repeat	NULL
III	NULL
,	NULL
5'-TCGACGTCCTCAGGC-GTTGACGACAACCCTCAG-3	NULL
'	NULL
;	NULL
mutated	NULL
A	NULL
box	NULL
21	NULL
bp	NULL
III	NULL
,	NULL
ACGTCCTCGAATGTTGACGACAACCCCTCAC-3	NULL
'	NULL
;	NULL
mutated	NULL
B	NULL
box	NULL
21	NULL
bp	NULL
III	NULL
,	NULL
5-TCGACGTCCTCAGGCGTCAATAACAACCCCTCAC-3	NULL
'	NULL
;	NULL
mutated	NULL
C	NULL
box	NULL
21	NULL
bp	NULL
III	NULL
,	NULL
5-TCGACGTCCTCAGGCGTTGACGA-CAATTATTCAC-3	NULL
'	NULL
;	NULL
mutated	NULL
A	NULL
and	NULL
C	NULL
boxes	NULL
III	NULL
,	NULL
5-TCGACGTC-CTCGAATGTTGACGACAATTATTCAC-3	NULL
'	NULL
;	NULL
mutated	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
boxes	NULL
III	NULL
5-CGACGTCCTCGAATGTCAATAACAATTATTCAC-3	NULL
'	NULL
;	NULL
metallothionein	NULL
5-TCGACTGACCGCCCGCGGCCCGTTGTGCAGC-3	NULL
'	NULL
.	NULL

HTLV-I	NULL
LTR	NULL
CAT	NULL
deletion	NULL
constructs	NULL
All	NULL
constructs	NULL
containing	NULL
the	NULL
HTLV-I	NULL
LTR	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
pUC19	NULL
polylinker	NULL
of	NULL
pJGFCAT	NULL
(	NULL
Garcia	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
site-directed	NULL
mutagenesis	NULL
(	NULL
Amersham	NULL
)	NULL
was	NULL
performed	NULL
to	NULL
introduce	NULL
the	NULL
identical	NULL
mutations	NULL
into	NULL
the	NULL
A	NULL
box	NULL
as	NULL
shown	NULL
in	NULL
the	NULL
A	NULL
box	NULL
mutated	NULL
oligonucleotides	NULL
used	NULL
in	NULL
gel	NULL
retardation	NULL
analysis	NULL
.	NULL

An	NULL
additional	NULL
site-directed	NULL
mutation	NULL
(	NULL
T-C	NULL
at	NULL
position	NULL
-120	NULL
)	NULL
was	NULL
introduced	NULL
for	NULL
cloning	NULL
purposes	NULL
.	NULL

The	NULL
wild-type	NULL
HTLV-I	NULL
LTR	NULL
construct	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
a	NULL
Smal	NULL
(	NULL
-323	NULL
)	NULL
~Hhal	NULL
(	NULL
+24	NULL
)	NULL
end-filled	NULL
fragment	NULL
into	NULL
the	NULL
Smal	NULL
site	NULL
in	NULL
pJGFCAT	NULL
.	NULL

The	NULL
-210	NULL
construct	NULL
contained	NULL
an	NULL
end-filled	NULL
Aval	NULL
-fhal	NULL
fragment	NULL
;	NULL
the	NULL
-	NULL
167	NULL
construct	NULL
contained	NULL
an	NULL
A/lul-H/al	NULL
end-filled	NULL
fragment	NULL
;	NULL
and	NULL
the	NULL
-120	NULL
fragment	NULL
contained	NULL
an	NULL
Niall	NULL
-Hhal	NULL
end-filled	NULL
fragment	NULL
.	NULL

These	NULL
fragments	NULL
were	NULL
all	NULL
inserted	NULL
into	NULL
pJGFCAT	NULL
19	NULL
restricted	NULL
with	NULL
Smal	NULL
or	NULL
SphI-Smal	NULL
.	NULL

The	NULL
-210	NULL
A-120/-55	NULL
construct	NULL
contained	NULL
the	NULL
end-filled	NULL
Aval-N/alll	NULL
fragment	NULL
joined	NULL
to	NULL
an	NULL
Ndel	NULL
(	NULL
-55	NULL
)	NULL
/Hhal	NULL
(	NULL
+24	NULL
)	NULL
end-filled	NULL
fragment	NULL
and	NULL
the	NULL
-323	NULL
A-210/-55	NULL
fragment	NULL
contained	NULL
a	NULL
Smal	NULL
(	NULL
-323	NULL
)	NULL
-Aval	NULL
(	NULL
-210	NULL
)	NULL
fragment	NULL
joined	NULL
to	NULL
an	NULL
Ndel	NULL
(	NULL
-55	NULL
)	NULL
/Hhal	NULL
(	NULL
+24	NULL
)	NULL
end-filled	NULL
fragment	NULL
.	NULL

Each	NULL
construct	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
Smal	NULL
site	NULL
of	NULL
pJGFCAT	NULL
19	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
assays	NULL
Jurkat	NULL
,	NULL
HUT78	NULL
and	NULL
SLB	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
and	NULL
10	NULL
%	NULL
FBS	NULL
with	NULL
penicillin	NULL
and	NULL
streptomycin	NULL
.	NULL

Cells	NULL
were	NULL
diluted	NULL
1:3	NULL
in	NULL
fresh	NULL
medium	NULL
on	NULL
the	NULL
day	NULL
prior	NULL
to	NULL
transfection	NULL
.	NULL

1.5	NULL
x	NULL
10	NULL
'	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electro-poration	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
250	NULL
ul	NULL
using	NULL
a	NULL
capacity	NULL
of	NULL
1180	NULL
uF	NULL
loaded	NULL
at	NULL
250	NULL
V.	NULL
Cells	NULL
were	NULL
then	NULL
incubated	NULL
for	NULL
16	NULL
h.	NULL
Half	NULL
of	NULL
the	NULL
sample	NULL
was	NULL
then	NULL
transferred	NULL
to	NULL
a	NULL
new	NULL
flask	NULL
and	NULL
induced	NULL
with	NULL
TPA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

,	NULL
PHA	NULL
(	NULL
4	NULL
ug/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
2	NULL
aM	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
8	NULL
h	NULL
and	NULL
one-quarter	NULL
of	NULL
the	NULL
extract	NULL
was	NULL
used	NULL
for	NULL
CAT	NULL
assays	NULL
(	NULL
Gorman	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

HepG2	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
DMEM	NULL
with	NULL
penecillin	NULL
and	NULL
streptomycin	NULL
and	NULL
10	NULL
%	NULL
FBS	NULL
.	NULL

Cultures	NULL
were	NULL
split	NULL
on	NULL
the	NULL
day	NULL
prior	NULL
to	NULL
transfection	NULL
and	NULL
used	NULL
at	NULL
40-50	NULL
%	NULL
confluency	NULL
.	NULL

Transfection	NULL
by	NULL
calcium	NULL
phosphate	NULL
precipitation	NULL
,	NULL
and	NULL
CAT	NULL
assays	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Gorman	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

Acknowledgements	NULL
We	NULL
wish	NULL
to	NULL
thank	NULL
Warner	NULL
Greene	NULL
for	NULL
supplying	NULL
a	NULL
tax	NULL
cDNA	NULL
,	NULL
Dixie	NULL
Shurland	NULL
for	NULL
technical	NULL
assistance	NULL
and	NULL
Chuck	NULL
Leavitt	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Health	NULL
,	NULL
Veterans	NULL
Administration	NULL
,	NULL
and	NULL
UC	NULL
AIDS	NULL
Task	NULL
Force	NULL
.	NULL

R.G	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
an	NULL
American	NULL
Cancer	NULL
Society	NULL
Faculty	NULL
Research	NULL
Award	NULL
and	NULL
C.M	NULL
.	NULL

from	NULL
a	NULL
NATO	NULL
grant	NULL
.	NULL

References	NULL
Altman	NULL
,	NULL
R.	NULL
,	NULL
Harrich	NULL
,	NULL
D.	NULL
,	NULL
Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Gaynor	NULL
,	NULL
R.B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
62	NULL
,	NULL
1339-1346	NULL
.	NULL

BÃ©raud	NULL
,	NULL
C.	NULL
,	NULL
Lombard-Platet	NULL
,	NULL
G.	NULL
,	NULL
Michal	NULL
,	NULL
Y.	NULL
and	NULL
Jalinot	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
10	NULL
,	NULL
3795-3803	NULL
.	NULL

Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Duvall.J.F	NULL
.	NULL

,	NULL
GÃ©gonne	NULL
,	NULL
A.	NULL
,	NULL
Bailly	NULL
,	NULL
M.	NULL
,	NULL
HÃ©mar	NULL
,	NULL
A.	NULL
,	NULL
Brady	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
3137-3144	NULL
.	NULL

Brady.J	NULL
.	NULL

,	NULL
Jeang.K.T	NULL
.	NULL

,	NULL
Duvall	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Khoury	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
61	NULL
,	NULL
2175-2181	NULL
.	NULL

Chen	NULL
,	NULL
L.S.Y	NULL
.	NULL

,	NULL
Slamon	NULL
,	NULL
D.J..	NULL
Rosenblatt	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
Shah	NULL
,	NULL
Queen	NULL
,	NULL
$	NULL
.G	NULL
.	NULL

and	NULL
Wachsman	NULL
.	NULL

W.	NULL
(	NULL
1985	NULL
)	NULL
Science	NULL
,	NULL
229	NULL
,	NULL
54-58	NULL
.	NULL

Clapham	NULL
,	NULL
P.	NULL
,	NULL
Nagy	NULL
.K	NULL
.	NULL

,	NULL
Cheimgsong-Popov.R	NULL
.	NULL

and	NULL
Weiss.R	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Science	NULL
,	NULL
222	NULL
,	NULL
1125-1127	NULL
.	NULL

Dignam.J.D	NULL
.	NULL

,	NULL
Lebowitz.R.M	NULL
.	NULL

and	NULL
Roeder.R.G	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
11	NULL
,	NULL
1475-1489	NULL
.	NULL

Felber.B.K	NULL
.	NULL

,	NULL
Paskalis	NULL
,	NULL
H.	NULL
,	NULL
Kleinmann-Ewing	NULL
,	NULL
C..	NULL
Wong-Staal	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Pavlakis	NULL
,	NULL
G.N	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Science	NULL
,	NULL
229	NULL
,	NULL
675-679	NULL
.	NULL

AP-2	NULL
activation	NULL
of	NULL
HTLV-I	NULL
Fujisawa	NULL
,	NULL
J.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Kiyokawa	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Yoshida	NULL
,	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
82	NULL
,	NULL
2277-2281	NULL
.	NULL

Fujisawa	NULL
,	NULL
J.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Seto	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Yoshida	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
5	NULL
,	NULL
713-718	NULL
.	NULL

Fujisawa	NULL
,	NULL
J.	NULL
,	NULL
Toita	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Yoshida	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
63	NULL
,	NULL
3234-3239	NULL
.	NULL

Garcia	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Harrich	NULL
,	NULL
D.	NULL
,	NULL
Soultanakis	NULL
,	NULL
E.	NULL
,	NULL
Wu	NULL
,	NULL
F.	NULL
,	NULL
Mitsuyasu	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Gaynor	NULL
,	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
765-778	NULL
.	NULL

Gessain	NULL
,	NULL
A.	NULL
,	NULL
Barin	NULL
,	NULL
F.	NULL
,	NULL
Vernant	NULL
,	NULL
J.C.	NULL
,	NULL
Gout	NULL
,	NULL
O.	NULL
,	NULL
Maurs	NULL
,	NULL
L.	NULL
,	NULL
Calender	NULL
,	NULL
A.	NULL
and	NULL
de	NULL
The	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Lancet	NULL
,	NULL
ii	NULL
,	NULL
407-410	NULL
.	NULL

Gitlin	NULL
,	NULL
S.	NULL
,	NULL
Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Gegonne	NULL
,	NULL
A.	NULL
,	NULL
Ghysdael	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Brady	NULL
,	NULL
J.N	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
Â§5	NULL
,	NULL
5513-5523	NULL
.	NULL

Gorman	NULL
,	NULL
C	NULL
.	NULL

M.	NULL
,	NULL
Moffat	NULL
,	NULL
L.F	NULL
.	NULL

and	NULL
Howard	NULL
,	NULL
B.H	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
1044-1051	NULL
.	NULL

Hai	NULL
,	NULL
T.	NULL
,	NULL
Liu	NULL
,	NULL
F.	NULL
,	NULL
Coulo	NULL
,	NULL
W.	NULL
and	NULL
Green	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
3	NULL
,	NULL
2083-2090	NULL
.	NULL

Hinrichs	NULL
,	NULL
S.H	NULL
.	NULL

,	NULL
Nerenberg	NULL
,	NULL
M.	NULL
,	NULL
Reynolds	NULL
,	NULL
S.R.K	NULL
.	NULL

,	NULL
Khoury	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Jay	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Science	NULL
,	NULL
237	NULL
,	NULL
1340-1343	NULL
.	NULL

Hoeffler	NULL
,	NULL
J.P.	NULL
,	NULL
Meyer	NULL
,	NULL
T.E	NULL
.	NULL

,	NULL
Yun	NULL
,	NULL
Y.	NULL
,	NULL
Jameson	NULL
,	NULL
J.L	NULL
.	NULL

and	NULL
Haebner	NULL
,	NULL
J.F	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
,	NULL
242	NULL
,	NULL
1430-1433	NULL
.	NULL

Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
,	NULL
51	NULL
,	NULL
251-260	NULL
.	NULL

Jeang	NULL
.	NULL

,	NULL
K.T	NULL
.	NULL

,	NULL
Boros	NULL
,	NULL
I.	NULL
,	NULL
Brady	NULL
,	NULL
J.	NULL
,	NULL
Radonovich	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Khoury	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
62	NULL
,	NULL
4499-4509	NULL
.	NULL

Jeang.K.T	NULL
.	NULL

,	NULL
Widen	NULL
,	NULL
$	NULL
.G	NULL
.	NULL

,	NULL
Semmes,0.J	NULL
.	NULL

and	NULL
Wilson	NULL
,	NULL
S.H	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
,	NULL
247	NULL
,	NULL
1082-1084	NULL
.	NULL

Koeffler	NULL
,	NULL
H.P	NULL
.	NULL

,	NULL
Chen	NULL
,	NULL
I.S.Y	NULL
.	NULL

and	NULL
Golde	NULL
,	NULL
D.W.	NULL
(	NULL
1984	NULL
)	NULL
Blood	NULL
,	NULL
64	NULL
,	NULL
482-490	NULL
.	NULL

Luscher	NULL
,	NULL
B.	NULL
,	NULL
Mitchell	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
Williams	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
3	NULL
,	NULL
1507-1517	NULL
.	NULL

Maekawa	NULL
,	NULL
T.	NULL
,	NULL
Sakura	NULL
,	NULL
H.	NULL
,	NULL
Kaneii-Ishii	NULL
,	NULL
C.	NULL
,	NULL
Sudo	NULL
,	NULL
T.	NULL
,	NULL
Yoshimura	NULL
,	NULL
T.	NULL
,	NULL
Fujisawa	NULL
,	NULL
J.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
and	NULL
Ishii	NULL
,	NULL
S	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
2023-2028	NULL
.	NULL

Marriot	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Boros	NULL
,	NULL
I.	NULL
,	NULL
Duvall	NULL
,	NULL
J.F	NULL
.	NULL

and	NULL
Brady	NULL
,	NULL
J.N	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
4152-4160	NULL
.	NULL

Marriot	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Lindholm	NULL
,	NULL
P.F	NULL
.	NULL

,	NULL
Brown	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Gitlin	NULL
,	NULL
$	NULL
.D	NULL
.	NULL

,	NULL
Duvall	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
Radonovich	NULL
,	NULL
M.F	NULL
.	NULL

and	NULL
Brady	NULL
,	NULL
J.N	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
4192-4202	NULL
.	NULL

Mitchell	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
Wang	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
,	NULL
50	NULL
,	NULL
847-861	NULL
.	NULL

Montagne	NULL
,	NULL
J.	NULL
,	NULL
BÃ©raud	NULL
,	NULL
C.	NULL
,	NULL
Crenon	NULL
,	NULL
lI	NULL
.	NULL

,	NULL
Lombard-Platet	NULL
,	NULL
G.	NULL
,	NULL
Gazolo	NULL
,	NULL
L.	NULL
,	NULL
Sargent	NULL
,	NULL
A.	NULL
and	NULL
Jalinot	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
957-964	NULL
.	NULL

Nyborg	NULL
,	NULL
J.K	NULL
.	NULL

and	NULL
Dynan	NULL
,	NULL
W.S	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
265	NULL
,	NULL
8230-8236	NULL
.	NULL

Nyborg	NULL
,	NULL
J.K.	NULL
,	NULL
Dynan	NULL
,	NULL
W	NULL
.S	NULL
.	NULL

,	NULL
Chen,1.S	NULL
.	NULL

Y.	NULL
and	NULL
Wachsman	NULL
,	NULL
W.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
1457-1461	NULL
.	NULL

Nyborg	NULL
,	NULL
J.K.	NULL
,	NULL
Matthews	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
Yucel	NULL
,	NULL
J.	NULL
,	NULL
Walis	NULL
,	NULL
L.	NULL
,	NULL
Golde	NULL
,	NULL
W.T	NULL
.	NULL

,	NULL
Dynan	NULL
,	NULL
W.S	NULL
.	NULL

and	NULL
Wachsman	NULL
,	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
265	NULL
,	NULL
8227-8242	NULL
.	NULL

Osame	NULL
,	NULL
M.	NULL
,	NULL
Usuku	NULL
,	NULL
K.	NULL
,	NULL
Ijichi	NULL
,	NULL
N.	NULL
,	NULL
Amitani	NULL
,	NULL
H.	NULL
,	NULL
Igata	NULL
,	NULL
A.	NULL
,	NULL
Matsumoto	NULL
,	NULL
M.	NULL
and	NULL
Tara	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Lancet	NULL
,	NULL
i	NULL
,	NULL
1031-1032	NULL
.	NULL

Paskalis	NULL
,	NULL
H.	NULL
,	NULL
Felber	NULL
,	NULL
B.K	NULL
.	NULL

and	NULL
Pavlakis	NULL
,	NULL
G.N	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
6558-6562	NULL
.	NULL

Poiesz	NULL
,	NULL
B.F.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.W	NULL
.	NULL

,	NULL
Gazdar	NULL
,	NULL
A.F	NULL
.	NULL

,	NULL
Bunn	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
Minna	NULL
,	NULL
J.D	NULL
.	NULL

and	NULL
Gallo	NULL
,	NULL
R.C	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
,	NULL
7415-7419	NULL
.	NULL

Poiesz	NULL
,	NULL
B.F.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.W	NULL
.	NULL

,	NULL
Reitz	NULL
,	NULL
M.S	NULL
.	NULL

,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
$	NULL
S	NULL
.	NULL

and	NULL
Gallo	NULL
,	NULL
R.C	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Nature	NULL
,	NULL
294	NULL
,	NULL
268-271	NULL
.	NULL

Poteat	NULL
,	NULL
H.T	NULL
.	NULL

,	NULL
Kadison	NULL
,	NULL
P.	NULL
,	NULL
McGuire	NULL
,	NULL
K.	NULL
,	NULL
Park	NULL
,	NULL
L.	NULL
,	NULL
Park.R.E	NULL
.	NULL

,	NULL
Sodrowski	NULL
,	NULL
J.G	NULL
.	NULL

and	NULL
Haseltine	NULL
,	NULL
W.A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
63	NULL
,	NULL
1604-1611	NULL
.	NULL

Pozzatti	NULL
,	NULL
R.	NULL
,	NULL
Vogel	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Jay	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
413-417	NULL
.	NULL

Rosen	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
Park	NULL
,	NULL
R.	NULL
,	NULL
Sodroski	NULL
,	NULL
J.G	NULL
.	NULL

and	NULL
Heseltine	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
4919-4923	NULL
.	NULL

Seto	NULL
,	NULL
E.	NULL
,	NULL
Mitchell	NULL
,	NULL
P.J	NULL
.	NULL

and	NULL
Yen	NULL
,	NULL
T.S.B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
,	NULL
344	NULL
,	NULL
72-74	NULL
.	NULL

Shimotohno	NULL
,	NULL
K.	NULL
,	NULL
Takano	NULL
,	NULL
M.	NULL
,	NULL
Terunchi	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Miwa	NULL
,	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
8112-8116	NULL
.	NULL

Smith	NULL
,	NULL
M.R	NULL
.	NULL

and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
4	NULL
,	NULL
1875-1885	NULL
.	NULL

Smith	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
K.S	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
67	NULL
,	NULL
31-40	NULL
.	NULL

Sodroski	NULL
,	NULL
J.G	NULL
.	NULL

,	NULL
Rosen	NULL
,	NULL
C.	NULL
,	NULL
Goh	NULL
,	NULL
W.C.	NULL
and	NULL
Haseltine	NULL
,	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
,	NULL
225	NULL
,	NULL
381-385	NULL
.	NULL

Tan	NULL
,	NULL
T.H	NULL
.	NULL

,	NULL
Horikoshi	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Roeder	NULL
,	NULL
R.G	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
1733-1745	NULL
.	NULL

Tanaka	NULL
,	NULL
A.	NULL
,	NULL
Takahashi	NULL
,	NULL
C.	NULL
,	NULL
Yamaoka	NULL
,	NULL
.S	NULL
.	NULL

,	NULL
Nosaka	NULL
,	NULL
T.	NULL
,	NULL
Maki	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Hatanaka	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
1071-1075	NULL
.	NULL

Tsujimoto	NULL
,	NULL
A.	NULL
,	NULL
Nyunoya	NULL
,	NULL
H.	NULL
,	NULL
Morita	NULL
,	NULL
T	NULL
.	NULL

,	NULL
Seto	NULL
,	NULL
T.	NULL
and	NULL
Shimotohno	NULL
,	NULL
K	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
65	NULL
,	NULL
1420-1426	NULL
.	NULL

Wano	NULL
,	NULL
Y.	NULL
,	NULL
Feinberg	NULL
,	NULL
M.	NULL
,	NULL
Hosking	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Bogerd	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Greene	NULL
,	NULL
W.C.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
9733-9737	NULL
.	NULL

Williams	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1991a	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
5	NULL
,	NULL
670-682	NULL
.	NULL

Williams	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1991b	NULL
)	NULL
Science	NULL
,	NULL
251	NULL
,	NULL
1067-1071	NULL
.	NULL

Williams	NULL
,	NULL
T.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
Luscher	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
2	NULL
,	NULL
1557-1569	NULL
.	NULL

Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Miyoshi	NULL
,	NULL
I	NULL
.	NULL

and	NULL
Hinuma	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
79	NULL
,	NULL
2031-2035	NULL
.	NULL

Yoshimura	NULL
,	NULL
T.	NULL
,	NULL
Fujisawa	NULL
,	NULL
J.I	NULL
.	NULL

and	NULL
Yoshida	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
2537-2542	NULL
.	NULL

Received	NULL
on	NULL
December	NULL
13	NULL
,	NULL
1991	NULL
;	NULL
revised	NULL
on	NULL
March	NULL
24	NULL
,	NULL
1992	NULL
2581	NULL

